Delatestryl, a testosterone injection marketed by Endo Pharmaceuticals, may be associated with an increased risk of blood clots, heart attack, stroke, and death — especially among men over 65 and those with pre-existing heart disease. Lawsuits are now being filed in courts around the country on behalf of plaintiffs who allegedly suffered serious cardiovascular events due to their use of Delatestryl and other low-T therapies.
Delatestryl Lawsuit Reviews
Men who experienced heart attacks, strokes and other serious cardiovascular events while using Delatestryl may be entitled to compensation for their physical, emotional and financial damages. To learn if you might qualify to file a Delatestryl lawsuit, please contact Bernstein Liebhard LLP at (888) 994-5118 to obtain a free, no-obligation legal review.
What Is Delatestryl?
Delatestryl (Testosterone Enanthate Injection, USP) is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, specifically primary hypogonadism (and hypogonadotropic hypogonadism. Delatestryl may be used to stimulate puberty in carefully selected males with clearly delayed puberty, and it may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are one to five years postmenopausal.
Low-T Heart Studies
- November 2013: A scientific paper published in JAMA suggests that use of prescription testosterone treatments is associated with a 25.7% risk of cardiovascular side effects, compared to 19.9% for men who were not on the drugs.
- January 2014: A study publishes in PLoS One found that men over 65 were twice as likely to have a heart attack if they used low-T treatments, while men under 65 with pre-existing heart disease were three times as likely to have a heart attack if they used the drugs.
FDA Testosterone Warnings
- January 2014: The JAMA and PLoS One studies prompted the FDA to announce a an investigation of low-T therapies and their potential cardiovascular side effect.
- June 2014: The FDA orders new blood clot warnings for prescription testosterone treatments, specifically for venous blood clots such as pulmonary embolism and deep vein thrombosis. The agency noted that the drugs’ labeling already included a warning regarding blood clots associated with polycythemia. However, regulators determined that a more general warning was needed due to reports of venous blood clots occurring in the absence of the condition. Read More
- March 2015: The FDA completes its cardiovascular review of testosterone products, and orders low-T manufacturers to add new warnings to their drug labels regarding a possible association with heart attacks and strokes. Read More
Testosterone Litigation Update
- August 2014: A class action lawsuit launched in Canada claims that the manufacturer of Delatestryl failed to warn doctors and patients about its association with serious cardiovascular side effects. Read More
- June 2014: A multidistrict litigation has been created for all federally-filed testosterone lawsuits brought on behalf of men who allegedly suffered heart attacks, strokes and blood clots due to their use of ow-T therapies. The new litigation will be housed in the U.S. District Court, Northern District of Illinois. Read More
- April 2014: Plaintiffs who have filed testosterone treatment lawsuits over the drugs’ alleged cardiovascular side effects have asked to have all federal cases centralized in a single U.S. District Court. They argue that centralization is appropriate because the lawsuits pose common questions of law and fact, and will ensure efficient management of the litigation and avoid duplicative discovery. Read More
Are You Eligible to File a Delatestryl Lawsuit?
You may be eligible to file a Delatestryl lawsuit if you suffered a serious cardiovascular event while using this low-T treatment. To learn more about the growing testosterone litigation, please call (888) 994-5118.
Last Modified: February 24, 2016